TRILEPTAL is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures
Manufacturer # 00078035752
Brand TRILEPTAL®
Manufacturer Novartis
Country of Origin Unknown
Application Anticonvulsant
Container Type Bottle
Dosage Form Suspension
Generic Drug Name Oxcarbazepine
Is_Active_Vendor Y
Is_DSCSA N
Is_Discontinued N
Is_Medical_Device Y
Lot_Tracking_Flag N
NDC Number 00078035752
On_Allocation N
Product Dating McKesson Acceptable Dating: we will ship >= 90 days
Strength 300 mg / 5 mL
Supplier_ID 3885243
Type Oral
UNSPSC Code 51141522
Volume 250 mL
